Tests nicotinamide, a vitamin B3, to slow vision loss in glaucoma
Tests nicotinamide tablets against a placebo in adults with open-angle glaucoma.
Key facts
- Who runs it
- University College, London
- Where
- Belfast, Cambridge, East Grinstead, Liverpool, London, Manchester, Nottingham, and Portsmouth, United KingdomSee the 10 sites
- Trial code
- Registry title
- Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 496 people, planned
- Started
- 18 Jan 2024
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Nicotinomide
- Matching placebo
- Record updated
- 9 May 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults recently diagnosed with early to moderate open-angle glaucoma who already use treatment to lower eye pressure. It tests whether nicotinamide (vitamin B3) slows sight loss.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Open-angle glaucoma diagnosed within the last 12 months, early to moderate, in at least one eye. This includes primary open-angle glaucoma, normal tension glaucoma and pseudoexfoliation glaucoma. Open angle on gonioscopy.
- Earlier treatment
- Standard care to lower eye pressure (drops or laser). Cannot be taking extra vitamin B3/NAM, Ginkgo Biloba or Coenzyme Q10 supplements, and cannot have been in a previous glaucoma trial.
- Biomarker or test result
- Visual field mean deviation no worse than -12dB in either eye. Snellen visual acuity 6/12 or better in at least one eye meeting the visual field criteria. Women who could become pregnant need a negative pregnancy test.
Main reasons for not taking part
- Pigment dispersion glaucoma
- Pregnancy, planned pregnancy or breastfeeding
- Liver disease or high liver enzymes (AST or ALT >3 x ULN), or kidney failure (eGFR <30mL/min/1.73m²)
- Another eye or brain condition that affects the visual field test, such as diabetic retinopathy or dementia
- Cancer diagnosed in the last 5 years (except non-melanoma skin cancer)
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patients who have been recently diagnosed (within the last 12 months) with early to moderate open-angle glaucoma (OAG) in at least one eye (including primary OAG, normal tension glaucoma (NTG) and pseudoexfoliation glaucoma)
- Open angle on gonioscopy
- Adults aged 18 years or over
- Snellen visual acuity 6/12 or better in at least one eye meeting the visual field (VF) criteria
- Visual Field (VF) mean deviation (MD) no worse than -12dB in either eye
- A negative pregnancy test result at the screening and baseline visit prior to randomisation for women of childbearing potential
- Ability to provide informed consent to participate
- Able and willing to attend trial visits and comply with trial procedures for the duration of the trial
Who cannot take part
- Current treatment with either isoniazid, pyrazinamide, carbamazepine, phenobarbital or primidone
- Concurrently enrolled in any other interventional trial or participation in previous clinical trial of glaucoma
- Conditions affecting both eyes which may affect the Visual Field test result:; Diabetic retinopathy or any other retinal disease causing VF loss; Clinically relevant cataract (likely to require cataract surgery within the next 2 years); Dementia or other non-glaucomatous neurological disease causing VF loss; Adnexal conditions causing VF loss (including but not limited to blepharochalasis)
- Diagnosed with cancer in the last 5 years (with exception of non-melanoma skin cancer)
- Any clinical condition that, in the investigator's opinion would make the participant unsuitable for the trial
- Current liver disease or laboratory results with elevated levels of liver transaminases (AST or ALT >3 x ULN) at screening visit
- Renal failure (eGFR <30mL/min/1.73m²) at screening visit
- Pigment dispersion glaucoma
- Pregnancy (or planned pregnancy during the trial) and/or breastfeeding
- Women of childbearing potential and male participants with a partner of childbearing potential not willing to use highly effective contraception for the duration of the trial treatment and for the time period specified following last trial treatment administration
- Current use of, and unwilling to abstain from, over-the-counter additional vitamin B3/NAM oral supplements (including skin preparations such as ointments/emulsions), Ginkgo Biloba and/or Coenzyme Q10 supplements, throughout the duration of their participation in the trial
Where in United Kingdom
- Belfast City HospitalBelfast, United KingdomContact: Augusto Azuara-Blanco (principal investigator)Not yet recruiting
- Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation TrustCambridge, United KingdomContact: Rupert Bourne (principal investigator)Not yet recruiting
- Queen Victoria Hospital NHS Foundation TrustEast Grinstead, United KingdomContact: Gokulan Ratnarajan (principal investigator)Taking people
- Royal Liverpool HospitalLiverpool, United KingdomContact: Neeru Vallabh (principal investigator)Not yet recruiting
- Barnet Hospital, Royal Free London NHS Foundation TrustLondon, United KingdomContact: Ameet Shah (principal investigator)Not yet recruiting
- King's College Hospital NHS Foundation TrustLondon, United KingdomContact: Gerassimos Lascaratos (principal investigator)Taking people
- Moorfields Eye Hospital NHS Foundation TrustLondon, United KingdomContact: David Garway-Heath (principal investigator)Taking people
- Manchester Royal Eye HospitalManchester, United KingdomContact: Jonathan Yu (principal investigator)Not yet recruiting
- Nottingham University Hospitals NHS TrustNottingham, United KingdomContact: Anthony King (principal investigator)Not yet recruiting
- Queen Alexandra HospitalPortsmouth, United KingdomContact: James Kirwan (principal investigator)Taking people
About the trial
What the trial wants to find out
Glaucoma is the leading cause of sight impairment and blindness worldwide. It is a long-term eye disease which can cause permanent loss of sight and sometimes blindness and affects 1 in 50 people over 50 years of age. Open-angle glaucoma (OAG) is the most common type of glaucoma. This tends to develop slowly over many years, caused by the drainage pathway in the eye gradually becoming blocked over time due to a build-up of fluid. This build-up causes pressure in the eye to increase (intra-ocular pressure (IOP)), which then damages the important nerve at the back of the eye called the optic nerve, resulting in vision loss. Current treatments offered for glaucoma (eye drops or laser surgery), aim to lower eye pressure and have shown to slow vision loss, however, visual disability and blindness rates remain unacceptably high and many patients continue to lose vision despite these treatments, suggesting that the optic nerve in some patients is more easily damaged. Recent research has looked at cells called 'mitochondria'. These cells produce most of the energy in the body, and the nerve cells in the eye need a lot of energy to function and survive. Nicotinamide (NAM) is a form of Vitamin B3 and evidence so far has shown that mitochondrial function can be improved with this treatment. The aim of this trial is to find out whether taking oral NAM when used with current standard treatment for lowering pressure in the eye, can reduce the amount of sight loss in recently diagnosed patients with OAG, and evaluate the long-term safety and effectiveness of NAM. The trial will use two groups of people recently diagnosed with glaucoma and who have normal care (drops or laser) to lower eye pressure. Using a method of randomisation (randomly allocated to each group using a computer system), one group will be given NAM and the other group will be given a placebo or 'dummy pill'. This is a double masked trial meaning the participant nor the Investigator will be told which treatment group patients have been allocated to.
The 2 groups in the trial
- NicotinamideTreatment being tested
Participants will receive Nicotinamide for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
Treatment: Nicotinomide
- Matching PlaceboPlacebo, for comparison
Participants will receive matching placebo for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Double-masked, Randomised, Placebo-controlled Trial Investigating the Safety and Efficacy of Nicotinamide (NAM) to Slow Visual Field Loss in Adults With Open-angle Glaucoma
- Plain-language title
- Tests nicotinamide, a vitamin B3, to slow vision loss in glaucomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 May 2024